Evolution of front-line immunotherapy for metastatic urothelial cancer.

Siefker-Radtke, Arlene O; Desai, Monica

Siefker-Radtke, Arlene O; Desai, Monica.

Affiliation

Siefker-Radtke AO; Department of Genitourinary Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA. Electronic address: asiefker@mdanderson.org.
Desai M; Department of Genitourinary Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.

Lancet Oncol ; 25(1): 2-3, 2024 Jan.

Article in En | MEDLINE | ID: mdl-38101432

Subject(s)

Carcinoma, Transitional Cell; Urinary Bladder Neoplasms; Humans; Carcinoma, Transitional Cell/pathology; Urinary Bladder Neoplasms/drug therapy; Urinary Bladder Neoplasms/pathology; Immunotherapy/adverse effects

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Database: MEDLINE Main subject: Urinary Bladder Neoplasms / Carcinoma, Transitional Cell Limits: Humans Language: En Year: 2024 Type: Article

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Database: MEDLINE Main subject: Urinary Bladder Neoplasms / Carcinoma, Transitional Cell Limits: Humans Language: En Year: 2024 Type: Article